SK Biopharmaceuticals Co., Ltd.
326030
Clasificación en acciones
#4038
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Precio por acción
$51.65
Capitalización bursátil
$4.05B
Cambio (1 día)
0.27%
Cambio (1 año)
-30.95%
País
KR
Comercio SK Biopharmaceuticals Co., Ltd. (326030)
Categoría
Healthcare
Ratio P/S de SK Biopharmaceuticals Co., Ltd. (326030)
Ratio P/S al October 2026 TTM: 6.31
Según los informes financieros más recientes y el precio de las acciones de SK Biopharmaceuticals Co., Ltd., el ratio P/S actual (TTM) es 6.31. Al final de 2024, el ratio P/S era 15.89.
Historial del ratio P/S de SK Biopharmaceuticals Co., Ltd. desde 2011 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 6.31 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 15.89 | -30.16% |
| 2023 | 22.75 | 0.17% |
| 2022 | 22.71 | 24.92% |
| 2021 | 18.18 | -96.10% |
| 2020 | 466.49 | 599.92% |
| 2019 | 66.65 | -99.07% |
| 2018 | 7.19K | 9,564.87% |
| 2017 | 74.43 | 5.37% |
| 2016 | 70.64 | -20.55% |
| 2015 | 88.91 | 2.53% |
| 2014 | 86.72 | 3.20% |
| 2013 | 84.03 | -14.35% |
| 2012 | 98.11 | -27.27% |
| 2011 | 134.89 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | 58.83% |
US
|
|
| 40.55 | 542.65% |
US
|
|
| 3.96 | -37.22% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 60.80% |
NL
|
